Affiliation:
1. Guangxi University of Chinese Medicine Nanning China
2. Department of Pharmacy Shenzhen Second People's Hospital Shenzhen China
3. Department of Pediatric Orthopedics Fuzhou Second Hospital Affiliated to Xiamen University Fuzhou China
4. Innovation Platform of Regeneration and Repair of Spinal Cord and Nerve Injury, The Seventh Affiliated Hospital Sun Yat‐sen University Shenzhen China
5. Department of Pharmacology Toxicology Shenzhen Institute for Drug Control Shenzhen China
Abstract
AbstractThe progression of osteoarthritis (OA) requires the involvement of inflammation, in which chondrocyte damage plays a significant role. Hydroxysafflor yellow A (HSYA), the main active component in the medical and edible dual‐purpose plant safflower, has previously shown anti‐inflammatory effects in various diseases. However, the specific impact of HSYA on OA remains unclear. Here, we investigate the potential role and underlying mechanism of HSYA in chondrocyte damage during the progression of OA. The viability of C28/I2 and iCell‐0092a chondrocytes was measured by CCK8 assay at different concentrations (2.5, 10, 40, and 160 μM). The gene expression of the extracellular matrix was revealed by q‐PCR 24 h after IL‐1β treatment. ROS production and levels of pro‐inflammatory cytokines in C28/I2 cells treated with HSYA were measured by immunoflurescence stating and q‐PCR. The impact of HSYA on the extracellular matrix and inflammation in IL‐1β‐induced OA were detected by western blot, q‐PCR, and immunofluorescence staining. We assessed the effect of HSYA and NF‐κB signaling pathway‐related genes by bioinformatics analysis and conducted molecular docking to assess the interaction of HSYA with a combined protein residue molecule ligand. Western blot was employed to investigate NF‐κB transcription factors in chondrocyte metabolism. HSYA was found to reduce excessive ROS production induced by IL‐1β stimuli, inhibit the expression of matrix metalloproteinase 13, interleukin 6, and tumor necrosis factor‐α, and increase the expression of Type II collagen and SRY‐box transcription factor 9 (p < .05). Mechanistically, HSYA interacted with nuclear factor κB, inhibiting the nuclear translocation and phosphorylation level of NF‐κB p65, and decreasing the phosphorylation and degradation of IκBα (p < .05). In conclusion, HSYA ameliorates inflammation and cartilage damage in OA by inhibiting the NF‐κB pathway, suggesting its potential application as a therapeutic agent for OA treatment.